QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Im-patient who wrote (878)	4/13/2000 7:04:00 AM
From: BostonView	Read Replies (1) of 1321

""Specifically, the FDA approved Visudyne therapy for the treatment of AMD in patients with predominantly classic subfoveal choroidal neovascularization (CNV). Medical experts estimate that of the 500,000 new patients that develop wet AMD every year around the world, 40-60% will develop predominantly classic lesions during the progression of their disease. Patients with this condition lose their ability to read, drive and recognize faces in as little as two months to three years. ``The approval of Visudyne therapy to treat AMD is a landmark event within the field of ophthalmology. As the first approved drug therapy for this devastating condition, Visudyne provides new hope to many of the 200,000 Americans who lose their vision from wet AMD every year,' said Luzi von Bidder, President of CIBA Vision's worldwide Ophthalmics Business Unit. ``This therapy will be available to eye care professionals and their patients across the country within 24 hours.' biz.yahoo.com Ian, others, what's the liklihood of some off-label use as can be so common with novel treatments? BV

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next